ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Bioqual Inc (PK)

Bioqual Inc (PK) (BIOQ)

67.50
0.00
( 0.00% )
Updated: 07:13:24

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
67.50
Bid
66.60
Ask
69.52
Volume
-
0.00 Day's Range 0.00
59.00 52 Week Range 80.00
Market Cap
Previous Close
67.50
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
334
Shares Outstanding
894,416
Dividend Yield
0.74%
PE Ratio
72.30
Earnings Per Share (EPS)
0.93
Revenue
62.66M
Net Profit
835k

About Bioqual Inc (PK)

BIOQUAL, Inc. is committed to providing quality research, model development, pre-clinical, testing/assay, and consulting services to commercial clients and Government laboratories. BIOQUAL, Inc. is committed to providing quality research, model development, pre-clinical, testing/assay, and consulting services to commercial clients and Government laboratories.

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Bioqual Inc (PK) is listed in the Coml Physical, Biologcl Resh sector of the OTCMarkets with ticker BIOQ. The last closing price for Bioqual (PK) was $67.50. Over the last year, Bioqual (PK) shares have traded in a share price range of $ 59.00 to $ 80.00.

Bioqual (PK) currently has 894,416 shares outstanding. The market capitalization of Bioqual (PK) is $60.37 million. Bioqual (PK) has a price to earnings ratio (PE ratio) of 72.30.

BIOQ Latest News

BIOQUAL Presents Financial Results for Fiscal Year 2014 and Declares Dividend

BIOQUAL:         2014 2013 Revenue $ 21,579,740 $ 20,204,308...

BIOQUAL, Inc., Announces Completion of the Purchase of ABL’s In-Vivo Animal Model Services Related Assets by BIOQUAL & Entr...

BIOQUAL, Inc. (BIOQUAL), announced today that it has completed its acquisition of ABL, Inc.’s (ABL) in-vivo animal model services-related assets. BIOQUAL and ABL will jointly market...

BIOQUAL & ABL, Inc. Announce Agreement for the Sale of ABL’s In-Vivo Animal Model Services Related Assets to BIOQUAL & Stra...

ABL, Inc. (ABL), and BIOQUAL, Inc. (BIOQUAL) announced today that they have signed a definitive agreement for BIOQUAL to acquire in-vivo animal model services-related assets from ABL. The...

BIOQUAL Presents Financial Results for Fiscal Year 2013

BIOQUAL, Inc. (Pinksheets: BIOQ):     2013 2012 Revenue $ 20,204,308 $ 22,667,149...

BIOQUAL Announces the Retirement of John C. Landon as Chief Executive Officer of BIOQUAL & the Appointment of Mark G. Lewis, ...

Dr. John C. Landon founded BIOQUAL in 1982. He led BIOQUAL for more than 30 years as President and Chief Executive Officer, and grew BIOQUAL to its current position as a $20M+ life...

Ex-Dividend

Sat, Nov 24, 2012 02:28 - BIOQUAL, Inc. (BIOQ: OTC Link) - Ex-Dividend - As of Mon, Nov 26, 2012, BIOQUAL, Inc. traded ex-dividend. BIOQUAL, Inc. will disburse a Cash Dividend dividend of $0.16...

Scheduled Ex-Dividend

Mon, Nov 12, 2012 08:00 - BIOQUAL, Inc. (BIOQ: OTC Link) - Scheduled Ex-Dividend - BIOQUAL, Inc. has announced a dividend ex-date for (BIOQ: OTC Link). BIOQUAL, Inc. is scheduled to disburse a...

BIOQUAL Presents Financial Results for Fiscal Year 2012 and Declares Dividend

BIOQUAL (Pinksheets: BIOQ):     2012 2011   Revenue $ 22,667,149...

BIOQUAL Announces That the National Cancer Institute Will Not Exercise the Final Option for a Mouse Breeding Facility

BIOQUAL (Pinksheets: BIOQ) has received notice from the National Cancer Institute (NCI) that the NCI will not be exercising its option to renew the contract “Facility for...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.5-3.57142857143707067.550067.875CS
4-2.5-3.57142857143707067.538368.15217391CS
12-5-6.8965517241472.572.567.533469.79962547CS
26-9.5-12.3376623377777767.533371.29554222CS
527.512.560805931370.97420174CS
156-15.5-18.674698795283108.55747678.15011032CS
26033.598.529411764734108.53454766.49908425CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AABVFAberdeen International Inc (PK)
$ 0.03115
(0.00%)
0
AABKFAareal Bank AG (PK)
$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
$ 0.03415
(0.00%)
39k
AAALYAareal Bank AG (PK)
$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
$ 0.55
(0.00%)
0
AABVFAberdeen International Inc (PK)
$ 0.03115
(0.00%)
0
AABKFAareal Bank AG (PK)
$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
$ 0.03415
(0.00%)
39k
AAALYAareal Bank AG (PK)
$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
$ 0.55
(0.00%)
0
OGCIFOceanaGold Philippines Inc OGP (GM)
$ 0.00
(0.00%)
800k
XIACFXiaomi Corporation (PK)
$ 2.5447
(0.00%)
500k
CHFLFChina Feihe Ltd (PK)
$ 0.407
(0.00%)
500k
DOCMFDr Martens PLC (PK)
$ 0.72
(0.00%)
450k
SHTDYSinopharm Group Company Ltd (PK)
$ 11.04
(0.00%)
386.21k

BIOQ Discussion

View Posts
AskMuncher AskMuncher 4 years ago
$BIOQ BIOQUAL Presents Financial Results for Fiscal Year 2020 and Declares Dividend
Press Release | 09/15/2020
BIOQUAL ((OTC Pink: BIOQ) (www.bioqual.com):



2020




2019




Revenue

$

46,360,201


$

39,478,079




Income Before Income Tax

$

5,488,938


$

3,709,246




Net Income

$

4,230,938


$

2,830,875




Basic Earnings per Share








of Common Stock

$

4.74


$

3.17


Diluted Earnings per Share








of Common Stock

$

4.73


$

3.17


Weighted Average








Number of Shares Outstanding






For Basic Per Share



893,416




893,416


Weighted Average








Number of Shares Outstanding






For Diluted Earnings Per Share



893,971




893,655

BIOQUAL’s Board of Directors has declared a dividend of $1.10 per share for shareholders of record on September 28, 2020, payable on October 21, 2020. This is the nineteenth dividend declared by BIOQUAL.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.


View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005969/en/
👍️0
Ubertino Ubertino 10 years ago
Get on a decent exchange!

Too easily to manipulate as an OTC-Pinky!

Get on a decent exchange - NYSE or affiliate - then I might be interested.
👍️0

Your Recent History

Delayed Upgrade Clock